Procedure for the determination of the activity of the protease which activates factor VII from protein solutions
AssigneeCSL Behring GmbH
InventorsJuergen Roemisch, Annette Feussner, Hans-Arnold Stoehr
Life of this patent
Estimating the term…
Abstract
A procedure for the determination of the activity of the protease which activates blood clotting factor VII from protein solutions is describes, in which the protein solution comprising the protease and/or its proenzyme is incubated with a solid phase to which an antibody which binds the protease and/or its proenzyme has been coupled beforehand, and after washing the solid phase, the protease and/or its proenzyme fixed thereto, are incubated with reagents which allow for the determination of their activity.
Claims15
1-13. (canceled)
A method of detecting whether an individual has increased or lowered activity of the protease that activates blood clotting factor VII compared to at least one standard sample, comprising:
- (a) obtaining a sample from the individual,
- (b) determining the activity of the protease that activates blood clotting factor VII in the sample,
- (c) determining the antigen content of the protease that activates blood clotting factor VII in the sample,
- (d) comparing the protease activity and the antigen content to the protease activity and antigen content of at least one standard sample, and
- (e) determining from (d) whether or not the individual has an increased or lowered activity of the protease that activates blood clotting factor VII compared to the at least one standard sample, wherein said increased or lowered activity indicates an increased risk for disease or cardiovascular complications.
A method of detecting whether an individual has 30-50% lower activity of the protease that activates blood clotting factor VII compared to at least one standard sample, comprising:
- (a) obtaining a sample from the individual,
- (b) determining the activity of the protease that activates blood clotting factor VII in the sample,
- (c) determining the antigen content of the protease that activates blood clotting factor VII in the sample,
- (d) comparing the protease activity and the antigen content to the protease activity and antigen content of at least one standard sample, and
- (e) determining from (d) whether or not the individual has 30-50% lower activity of the protease that activates blood clotting factor VII compared to the at least one standard sample, wherein said 30-50% lower activity indicates an increased risk for disease.
Dependencies are inferred from the claim text.